Proqr Therapeutics Bv Stock Performance
| PRQR Stock | USD 1.48 0.01 0.68% |
The company holds a Beta of 0.29, which implies not very significant fluctuations relative to the market. As returns on the market increase, ProQR Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ProQR Therapeutics is expected to be smaller as well. At this point, ProQR Therapeutics has a negative expected return of -0.58%. Please make sure to check ProQR Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if ProQR Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ProQR Therapeutics BV has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1 | ProQR Therapeutics Reports Q3 2025 Financial Results - TipRanks | 11/20/2025 |
2 | Brokerages Set ProQR Therapeutics N.V. Price Target at 7.14 | 01/23/2026 |
3 | ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com | 02/09/2026 |
| Begin Period Cash Flow | 118.9 M | |
| Total Cashflows From Investing Activities | -4.1 M |
ProQR Therapeutics Relative Risk vs. Return Landscape
If you would invest 216.00 in ProQR Therapeutics BV on November 13, 2025 and sell it today you would lose (74.00) from holding ProQR Therapeutics BV or give up 34.26% of portfolio value over 90 days. ProQR Therapeutics BV is currently does not generate positive expected returns and assumes 4.4965% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than ProQR, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ProQR Therapeutics Target Price Odds to finish over Current Price
The tendency of ProQR Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.48 | 90 days | 1.48 | roughly 96.0 |
Based on a normal probability distribution, the odds of ProQR Therapeutics to move above the current price in 90 days from now is roughly 96.0 (This ProQR Therapeutics BV probability density function shows the probability of ProQR Stock to fall within a particular range of prices over 90 days) .
ProQR Therapeutics Price Density |
| Price |
Predictive Modules for ProQR Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ProQR Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ProQR Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ProQR Therapeutics is not an exception. The market had few large corrections towards the ProQR Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ProQR Therapeutics BV, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ProQR Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 0.29 | |
σ | Overall volatility | 0.28 | |
Ir | Information ratio | -0.17 |
ProQR Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ProQR Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ProQR Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics may become a speculative penny stock | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.91 M. Net Loss for the year was (27.76 M) with profit before overhead, payroll, taxes, and interest of 16.07 M. | |
| ProQR Therapeutics BV currently holds about 156.4 M in cash with (36.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProQR Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com |
ProQR Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ProQR Stock often depends not only on the future outlook of the current and potential ProQR Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ProQR Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 81.7 M | |
| Cash And Short Term Investments | 149.4 M |
ProQR Therapeutics Fundamentals Growth
ProQR Stock prices reflect investors' perceptions of the future prospects and financial health of ProQR Therapeutics, and ProQR Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProQR Stock performance.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (3.87) % | ||||
| Current Valuation | 49.55 M | ||||
| Shares Outstanding | 105.35 M | ||||
| Price To Earning | (1.97) X | ||||
| Price To Book | 2.32 X | ||||
| Price To Sales | 9.70 X | ||||
| Revenue | 18.91 M | ||||
| Gross Profit | 16.07 M | ||||
| EBITDA | (24.12 M) | ||||
| Net Income | (27.76 M) | ||||
| Cash And Equivalents | 156.4 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 17.22 M | ||||
| Debt To Equity | 0.70 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.65 X | ||||
| Cash Flow From Operations | (36.39 M) | ||||
| Earnings Per Share | (0.49) X | ||||
| Market Capitalization | 155.91 M | ||||
| Total Asset | 167.96 M | ||||
| Retained Earnings | (427.16 M) | ||||
| Working Capital | 114.94 M | ||||
| Current Asset | 97.77 M | ||||
| Current Liabilities | 5.49 M | ||||
About ProQR Therapeutics Performance
Assessing ProQR Therapeutics' fundamental ratios provides investors with valuable insights into ProQR Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ProQR Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 383.68 | 304.41 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.36) | (0.34) |
Things to note about ProQR Therapeutics performance evaluation
Checking the ongoing alerts about ProQR Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProQR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics may become a speculative penny stock | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.91 M. Net Loss for the year was (27.76 M) with profit before overhead, payroll, taxes, and interest of 16.07 M. | |
| ProQR Therapeutics BV currently holds about 156.4 M in cash with (36.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProQR Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com |
- Analyzing ProQR Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProQR Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ProQR Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProQR Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProQR Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProQR Therapeutics' stock. These opinions can provide insight into ProQR Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.